# ISAGRO: GROWTH AND VALUE EXTRACTION, BASED ON OUR INNOVATION



Isagro SpA STAR Conference

London, October 6<sup>th</sup>, 2015








# FEEDING THE PLANET: THE «GAP» BETWEEN DEMAND AND SUPPLY OF FOOD ...

#### Today: imbalance between Demand and Supply of food ...




800 million people with inadequate access to food

### ... because, in spite of an important increase of the Supply, ...




## ... the Demand has grown more than proportionally


(for human and animal feeding and for industrial/energy use)




# "... WILL INCREASE OVER THE NEXT DECADES, REPRESENTING A CHALLENGE FOR AGRICULTURE

Over the next 35 years the world population is expected to reach over 9 billion people ...








1975 2005 2025 2050 (square meters of farming field per capita)

IT IS NECESSARY TO FURTHER (AND SIGNIFICANTLY) INCREASE YIELD PER HECTARE

# CROP PROTECTION PLAYS A KEY ROLE IN AGRICULTURE ...




### ... AND REPRESENTS A GLOBAL MARKET...




US\$ 57 Billion

(2014)
Estimated CAGR (EC)
to 2019: +2.6%

...and by product category




#### Breakdown by region...






### ... BASED ON INNOVATION ...

- Time to Market: 10-12 years
- Development cost for a new molecule: 100 to 200 USD million



# ... THUS CONCENTRATED, YET WITH ROOM FOR A PLAYER LIKE ISAGRO



### ISAGRO'S KEY FACTS & FIGURES

1993

Start-up of Isagro project, with a turnover below

• 50 M

Today

Turnover ~ €150M

(80% of which outside Italy)

2018

Turnover

> €200M

(based on projects underway)

1956

When our Innovation was founded (Montecatini/Montedison origin)


2003

IPO on the Milan Stock Exchange



### OUR BUSINESS MODEL: GLOBAL INDEPENDENT ORIGINATOR of molecules/solutions for Crop Protection

We are an integrated player based on Discovery, originating new molecules / solutions for Crop Protection worldwide



# OUR STRATEGY IS BASED ON OUR CAPABILITY TO INVENT AND TO BUILD ALLIANCES ...

- 1 TO ORIGINATE AND PRE-DEVELOP NEW MOLECULES, ALONE (Based on our Discovery)
- TO ASSURE A PROPER EXPLOITATION OF OUR INNOVATIONS ON A GLOBAL BASIS ALSO BY ATTRIBUTING RIGHTS TO THIRD PARTIES (Thus overcoming our limited size vs. large Originators)
- TO GROW IN THE BIOSOLUTIONS BUSINESS
  (Leveraging on our existing portfolio and innovation capability)
- TO EXPAND OUR DIRECT PRESENCE ON KEY-MARKETS (For local marketing & sales activities)

#### ... ON WHICH OUR BUSINESS PLAN LEVERAGES

Target: > 200 €M









#### Memo: First Half 2015 Results (€M)


#### **REVENUES**




**EBITDA** 



**NWC & NFP** 



# ISAGRO INTRODUCED "GROWTH SHARES", A NEW CATEGORY OF SHARES FOR COMPANIES ALREADY HAVING A «CONTROLLING SUBJECT» ...




20% vs. Ordinary Shares in the case of Isagro

In any case the Controlling Subject loses control and/or in case of Compulsory Public Offer (OPA)

# ... SUFFERING AN "UNJUSTIFIED" SPREAD VS. ORDINARY SHARES ...

In the 12-month period: ~11.7 million Ordinary Shares and ~5.9 million Growth Shares traded



\*Growth Shares are a new category of special shares, issuable by companies having a Controlling Subject, which against the absence of voting right:

- grant an extra-dividend vs. Ordinary Shares (20% in the case of Isagro);
- are automatically converted into Ordinary shares if the controlling Subject loses control and/or in any
  case of Compulsory Public Offer

# ... IN A SITUATION OF TOTAL MARKET CAPITALIZATION LOWER THAN BOOK VALUE

Price as of	Market
Oct. 2 <sup>nd</sup> , 2015 (€)	Capitalization (€ M)

ORDINARY SHARES	1.46	35.8
		00.0

GROWTH SHARES 1.15 16.3

MARKET CAP. 52.1

**EQUITY BOOK VALUE\*** 

97.7\*\*

Market capitalization ≤ Book Value



<sup>\*</sup> As of June 30<sup>th</sup>, 2015

<sup>\*\*</sup>Significantly lower than Net Assets Value

#### ATTACHMENT: OUR CORPORATE PROFILE

### ISAGRO: ITALIAN, INDEPENDENT ...

Listed on the Italian Stock Exchange (STAR\* segment)

### **Piemme**


Italian holding company indirectly controlling Isagro

Gowan

industrial partner with a minority stake

2/3

of total shares (Ordinary + Growth) floating in the marketplace



<sup>\*</sup> High Requirements Stock Segment of the Italian Stock Exchange (part of the LSE Group)

### AND BASED ON INNOVATION

Isagro is the only non-large Crop Protection company operating globally based on its own Innovative Research

- Research Center in Novara (Italy)
- Pilot plant in Panoli (India)
- Field-trial station in Galliera (Italy)





€ ~15 M annual expenditure in R,I&D

-100 People working in R,I&D


### DISCOVERED MOLECULES

- **Benalaxyl**
- **Biofungicide**
- **Biostimulants/Pheromones**
- **Kiralaxyl**
- **Novaluron**
- Orthosulfamuron
- SDHi class fungicide \*
- **Tetraconazole**
- **Valifenalate**

<sup>\*</sup>under co-development



# OUR DISCOVERY CAPABILITY ORIGINATES IN 1956 ...



# ... AND REPRESENTS THE BASE OF OUR BUSINESS MODEL, EVOLVED OVER THE TIME

Our Business Model experienced three "Phases"...

"Alliances to compete"

2<sup>nd</sup> phase: 2006-2012 "Developing by ourselves, for ourselves" 3rd phase: since 2013
"Assuring a proper exploitation of our discoveries also by attributing rights to third parties"


... always with a common basis:

our Discovery capability



### 1st PHASE OF ISAGRO: 1993-2005

«Alliances to compete»




- System of Strategic Alliances also for Discovery
- Commercial development of Tetraconazole fungicide



### 2<sup>nd</sup> PHASE OF ISAGRO: 2006-2012

«Developing by ourselves, for ourselves only»




- Development of two new molecules «by ourselves»
- Exploitation of our intellectual property (existing products) «for ourselves only»
- Acquisition and then divestment of distribution participations

<u>LESSON</u>: we are good at inventing but, if we develop alone, we under-exploit the potential of our inventions



### 3rd PHASE OF ISAGRO: SINCE 2013

«Assuring a proper exploitation of our discoveries also by attributing rights to third parties»



- Discovery and Pre-Development of new molecules alone
- Development of new molecules by attributing rights to third parties for those products/markets/segments where Isagro alone could not extract an adequate value

Thus overcoming the constraint of our size vis-à-vis the global market potential of our inventions



# OUR PORTFOLIO IS LARGELY REPRESENTED BY PROPRIETARY PRODUCTS ...


2014 revenues breakdown

By product category

TOTAL REVENUES = 146 €M (+4.4% vs. 2013)



By region (Crop Protection only)














### ... MAINLY FOCUSED ON FUNGICIDES



# WE ARE INTEGRATED IN MANUFACTURING ...

• Panoli (India) strategic site for the synthesis of proprietary active IN ITALY IN INDIA ingredients Galliera Novara Field-trial station - Research Center - Fermentation of Biological products **Aprilia Panoli** Adria Formulation Synthesis and - Synthesis and **Formulation** Formulation of Process development Copper products - Pilot plant Bussi Synthesis of Tetraconazole

• 5 plants (4 in Italy and

1 in India)

# ... AND WE HAVE A GLOBAL PRESENCE

€ ~150 M turnover

Sales in over 70 countries

Direct distribution in Colombia, India, Spain and USA



Over 600 employees



**ISAGRO** 

Isagro is also present in Argentina, Australia, Chile and South Africa with companies established to register products of the Group. (Companies in South-East Asia and in Turkey are under incorporation)



# AWARDS



"Bocconi University centenary"

Isagro presented as case of success

2004



**"Best Innovator"** (Italy)

Promoted by AT Kearney and Confindustria

2005



Category "Finance" (Italy)

Promoted by Ernst&Young

2006




Category "Made in Italy in the world»

2007

"Champion of growth" (Italy)

Promoted by Confindustria, Cerved, McKinsey and Bocconi University 2013



(Italy)

Promoted by CG Consulting for corporate governance - category "Presidents" 2013

"Assiteca prize"

(Italia)

In co-operation with Il Sole 24 Ore - for companies investing in risk management - Category «Large Enterprises»



#### **For information:**

#### **Ruggero Gambini**

Chief Financial Officer
& IR Manager

tel. (+39) 02.40901.259

#### **Erjola Alushaj**

Financial Planner & assistant to IR

tel. (+39) 02.40901.340







email: ir@isagro.it

www.isagro.com



Estimates, considerations, statements and opinion, except for what referring to actual figures, are to be considered as data, estimates, considerations, statements and opinion regarding future, and have been elaborated and stated on the basis of available information and/or on the basis of those information considered the most reliable and/or the most reasonable.

Such data, estimates, considerations, statements and opinion could prove to be incomplete and/or wrong and they incorporate elements of risk of uncertainty, beyond the company control. For such reasons, actual results may prove to differ versus data, estimates, considerations, statements and opinion contained in such presentation.

Any reference to Isagro products is to be considered exclusively as general information about the group activity and is not to be intended, under any circumstances, as invitation to employ or propose the employment of such products.

Such data, estimates, considerations, statements and opinion are not to be considered as a proposal of investment, under any circumstances, in Isagro's shares.